From CounterPunch: “When a loved one dies is your grief a ‘psychiatric condition’ requiring medication? Why is a vial of insulin, once produced for five dollars, now $300? Is the Alzheimer’s amyloid model accurate in light of weak correlations to actual improved cognition—and new treatments so expensive they threaten to raise Medicare premiums? And finally, does early cancer detection have concerning drawbacks?
These volatile questions characterized the 9th conference of PharmedOut, a Georgetown University Medical Center project, held in June.
Created by a two-year grant from Pfizer’s 2004 off-label neurontin settlement—its Warner-Lambert unit pleaded guilty to off-label marketing—PharmedOut’s focus is to educate healthcare professionals about pharmaceutical marketing practices.”
***
Back to Around the Web
